Partners
Meet our partners
Forging alliances for progress
The following is a selected list of our commercial and licensing partners. Will you join this network dedicated to advancing novel and effective vaccines?
Commercial partners
Therapyx
Therapyx, based in Buffalo, NY, is a privately held development-stage biotechnology company committed to innovating our industry and changing the future of pharmaceuticals by engaging in the discovery and development of microparticulate immune therapeutics to treat infectious disease, immune-mediated inflammatory disorders, and cancer. Intravacc collaborates with Therapyx to further develop and optimize a prophylactic vaccine against gonorrhea. The vaccine consists of Outer Membrane Vesicles from the bacterium Neisseria gonorrhoeae, developed with Intravacc’s OMV platform and microsphere-encapsulated interleukin-12 (IL-12). Thus, this vaccine consists of a combination of adjuvant and antigen and is specifically designed for mucosal immunization.
Liaoning Chengda Biotechnology CO., Ltd.
Liaoning Chengda Biotechnology CO., Ltd. (CDBIO) holds a prominent position in the field of human vaccines and associated products and technologies within the People’s Republic of China. Currently, CDBIO is engaged in a collaborative effort with Intravacc to advance the development of a vaccine targeting meningococcal type B disease, utilizing Intravacc’s proprietary Nonamen® vaccine technology. Both organizations are actively working together to customize the Nonamen concept to align with the specific needs of the Chinese market.
Changchun BCHT Biotechnology, Co.
Established in 2004 and situated in Changchun, Changchun BCHT Biotechnology Co. (BCHT) is a biopharmaceutical enterprise specializing in research, development, production, and marketing of vaccines, biologics, and peptide drugs. Intravacc and BCHT collaborate on the ongoing development of a Haemophilus influenzae Type B (HiB) conjugate vaccine within the People’s Republic of China. Through this partnership, BCHT has gained access to Intravacc’s unique Hib conjugate technology for the further development, production, and distribution of the vaccine. This vaccine comprises Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled with tetanus toxoid, proving highly effective in preventing the disease. Intravacc’s Hib vaccine technology has already been employed to vaccinate hundreds of millions of children and holds WHO prequalification.
Sinovac
Sinovac is a China-based Biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines for infectious disease with significant unmet medical need. Intravacc and Sinovac are collaborating in the eradication of polio through the technology transfer of sIPV vaccine technology. Sinovac received market authorization for its sIPV vaccine in July 2021.
LG Chem
Established in 1947, LG Chem has grown to become Korea’s leading chemical company. Intravacc successfully transferred its sIPV technology to LG Chem and supported its implementation at the LG Chem site. Clinical studies for the vaccine have been completed and market licensure and WHO-prequalification have been obtained. Commercial manufacturing of the vaccines is ongoing as part of the Polio Eradication Campaign.
Beijing Minhai
Beijing Minhai is primarily engaged in the development, production, and sale of biological vaccine products. Intravacc and Minhai are currently collaborating on implementing the sIPV (Sabin Inactivated Poliovirus Vaccine) technology at Minhai’s facilities. This sIPV vaccine technology developed by Minhai has progressed through Phase II clinical studies in China.
Awarded Public Funding
Several development projects at Intravacc are publicly funded by national and international agencies. Writing proposals aimed at acquiring funding for novel vaccine concepts is a core activity of the Translational Research Department of Intravacc. The following is a sample of awarded funding.
National and international agencies
U.S. National Institutes of Health (NIH)
In October 2022, Intravacc secured a 14.6 million USD contract from the US National Institute of Allergy and Infectious Diseases (NIAID) to develop an intranasal gonorrhea vaccine. The vaccine uses proprietary technology with IL-12-containing microspheres from Therapyx, Inc. and has demonstrated effectiveness in animal models, prompting further development. The project aims to advance the vaccine to phase I readiness study to evaluate safety and efficacy. Gonorrhea, a common sexually transmitted disease, lacks an effective vaccine, and antibiotic resistance is rising.
European Innovation Council Transition Grant
In July 2022, Intravacc and the German Center for Neurogenerative Diseases (DZNE) secured 2.5 million EUR in EU funding to advance the development of an experimental ALS vaccine. ALS is a progressive neurodegenerative disease with no current cure. The project, funded through the European Innovation Council Transition Grant, focuses on establishing pre-clinical efficacy of a vaccine prototype that targets toxic poly-GA molecules associated with the disease and caused by the C9orf72 gene mutation.
U.S. National Institutes of Health (NIH)
In September 2020, Intravacc was awarded a contract with base and options that may total 9.4 million USD from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that is associated with a form of childhood paralysis called acute flaccid myelitis (AFM). In this project, an inactivated EV D68 vaccine will be developed up to a phase I clinical study that is foreseen to start in 2026.
Coalition of Pandemic Preparedness Initiative (CEPI)
In October 2022, Intravacc was awarded a contract of 4.9 million USD from CEPI for the development of an Outer Membrane Vesicle-based, broadly protective beta coronavirus vaccine that builds on the technology of, Intravacc’s SARS-CoV-2 vaccine. The project aims to establish pre-clinical proof of concept of this innovative vaccine candidate.